Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 4 ans
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohepatitis (NASH)
• To investigate the safety and tolerability of multiple oral doses of GS 9450 in subjects with NASH
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
The primary objective of this study is to compare the change in 6-minute walk distance (6MWD) after initiating ambrisentan or placebo treatment in subjects with pulmonary hypertension (PH) associated ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study to compare two pediatric formulations to the adult formulation of cobicistat 150 mg tablet in healthy adult volunteers
To evaluate the relative bioavailability of two age-appropriate pediatric formulations (immediate release tablet or dispersible tablet as suspension) of COBI in healthy adult subjects
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease
To evaluate the antiviral efficacy of treatment with LDV/SOF for 8,12, or 24 weeks in subjects with chronic hepatitis C virus (HCV) infection who are on dialysis for ESRD, as measured by the proport...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Gilead Sciences
Update Il y a 4 ans
AmBiGuard : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité et la tolérance d’un traitement prophylactique des infections fongiques invasives par l’amphotéricine B liposomale, chez des patients ayant une leucémie aiguë lymphoblastique et recevant une chimiothérapie d’induction. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de l’amphotéricine B liposomale dans la prévention des infections fongiques invasives lors d’une chimiothérapie d’induction, chez des patients ayant ...
Country
France
organs
Leucémies aiguës
Specialty
Soins de Support
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for Adolescents and Children with hepatitis C
PK Lead-in phase is: To evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL) in pediatric subjects with chronic hepatitis C virus (HCV) infection ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Europe Ltd
Update Il y a 4 ans
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol
The primary objective is to determine if switching the NRTI backbone from Kivexa to Truvada leads to a reduction in fasting total cholesterol at 12 weeks.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A Phase 3, Double-Blind Extension Study of Idelalisib (GS-1101) at Different Dose Levels for Previously Treated CLL patients (a Companion Trial to GS-US-312-0116)
• To evaluate the effect idelalisib (formerly GS-1101) on the onset, magnitude, and duration of tumor control • To compare tumor control in subjects receiving rituximab alone in Study GS-US-312-0116...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
Bioavailabity and food effects of the paediatric formulation of LDV/SOF in adult subjects
To evaluate the relative bioavailability of a pediatric granules formulation of ledipasvir/sofosbuvir (LDV/SOF) relative to tablet formulation in healthy subjects. To evaluate the effect of conco...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study to test the safety, tolerability and ability to maintain HIV suppression of of switching from a current regimen consisting of abacavir/lamivudine (ABC/3TC) plus a third antiretroviral agent to the elvitegravir/cobicistat/emtricitabine/tenofovir Alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects who are virologically suppressed. Estudio para evaluar la seguridad, tolerabilidad y la capacidad de mantener la supresión de VIH al pasar de un régimen de abacavir / lamivudina (ABC/ 3TC) más un tercer agente antirretroviral a una combinación de dosis fija (FDC) de elvitegravir / cobicistat / emtricitabina / tenofovir alafenamida (E / C / F / TAF) ) en sujetos adultos infectados por el VIH-1 con supresión virológica
To evaluate the efficacy of switching to E/C/F/TAF FDC relative to continuing on a baseline regimen consisting of ABC/3TC plus a third antiretroviral agent in maintaining HIV-1 RNA < 50 copies/mL at W...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next